Arrowhead Research Corp. (NASDAQ:ARWR) on Aug. 12 announced financial results for its fiscal 2014 third quarter ended June 30, 2014 and provided an update on the Phase 2a study of ARC-520, its RNAi-based candidate for the treatment of chronic hepatitis B infection. Net loss attributable to Arrowhead for the quarter was $11.6 million, or $0.22 per share based on 51.9 million weighted average shares outstanding. … Continue reading Stocks in Focus : Arrowhead Research (NASDAQ:ARWR), Sonus Networks (NASDAQ:SONS), RGC (NASDAQ:RGCO), American Electric Power Co., Inc. (NYSE:AEP), American Science (NASDAQ:ASEI)